A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

RecruitingOBSERVATIONAL
Enrollment

490

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2032

Conditions
Ovarian Cancer
Interventions
DRUG

fluzoparib monotherapy or combination therapy

patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy

Trial Locations (1)

430030

RECRUITING

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

First Hospital of China Medical University

OTHER

collaborator

Cancer Hospital of Xinjiang Medical University

UNKNOWN

collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

collaborator

Qingyuan People's Hospital

OTHER

collaborator

Zhejiang University

OTHER

collaborator

Panzhihua Central Hospital

OTHER

collaborator

Liangshan First People's Hospital

UNKNOWN

collaborator

Guang'an People's Hospital

UNKNOWN

collaborator

Affiliated Hospital of North Sichuan Medical College

OTHER

collaborator

Cancer Hospital of Guizhou Province

OTHER

collaborator

Guizhou International General Hospital

UNKNOWN

collaborator

Yichang Central People's Hospital

OTHER

collaborator

Wuhan Fourth Hospital

UNKNOWN

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

lead

Tongji Hospital

OTHER